Privatization Moves In Eastern Europe

5 December 1994

The Latvian Privatization Agency has announced privatization details of two pharmaceutical plants. The first, the Olaine Chemical-Pharmaceutical Plant in Olaine, is about 40 kilometers south of Riga, the capital. It produces 1.5 billion tablets and 700 tonnes of pharmaceutical raw materials and 600 tonnes of by-products a year. It had a turnover of 4.3 million lats ($2.3 million) in 1993, and a workforce of 969 in mid-1994.

The Livani Biochemical Plant, located 175 kilometers south-east of Riga, produced 3,000 tonnes a year of concentrated forage lysine until 1992, when production was suspended. In mid-1994, the workforce numbered 64.

The closing date for bids for these plants is December 22, 1994. Further information, quoting reference number LV-21 for the Olaine plant and ref LV-49 for the Livani plant, from: Latvian Privatization Agency, K Valdemara iela 31, Riga, LV-1887, Latvia. Phone: +358 49 106103; fax: +358 49 106100/106101.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight